$INCY

Stein Steven H sold $3.2M of INCY

Stein Steven H (CMO & Head of Late-Stage Dev.) sold 28,237 shares of INCYTE CORP (INCY) at $113.05 ($3.19M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stein Steven H
Published Jul 16, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings; it does not introduce new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits interpretive value.

03

What to watch

The filing does not disclose any change in company guidance, trial results, or business performance; traders should avoid extrapolating fundamentals from a single planned sale.

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-07-16)

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an officer (CMO and Head of Late-Stage Development).

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows officer Stein Steven H sold 28,237 shares at $113.05 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, with no new operational, financial, or regulatory information disclosed.

Market effects

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying company-specific catalysts.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • INCY

    Incyte Corp, the subject of the Form 4 insider transaction.

  • Stein Steven H

    CMO and Head of Late-Stage Development who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.